Industry Analysis Reports | Health Care | Medical Devices

Sunday, 27 September 2020

Clinical Trial Management System Market reaching the value of USD 1,106.76 million with CAGR 12.0% by 2025

Global clinical trial management system market is witnessing a rapid increase in its revenues. This growth majorly attributes to the proliferating numbers of pharmaceutical and biotechnology companies. Rise in the global population is prompting the demand for effective & quality healthcare are driving the clinical trial management industry, increasing the number of clinical trials required for drug discoveries.

Get a FREE Sample Report with Complete TOC @ https://www.marketresearchfuture.com/sample_request/2054

Besides, substantial R&D investments made in the increasing numbers of contract manufacturing organizations (CMOs) are accelerating the demand for clinical trial management system technology. According to Market Research Future (MRFR), the global clinical trial management system market is projected to create a valuation of USD 1,631.3 MN by 2025, registering 12.0% CAGR over the forecast period (2019-2025).

The huge demand for CTMS and the growing healthcare IT companies influence market growth predominantly, providing client-specific software solutions. Additionally, factors such as the rise in the SaaS-based applications are contributing to the market growth, enhancing the performance of clinical trials. Besides, the rising demand for clinical trial management system services market substantiates the growth of the market.

Furthermore, increasing adoption of CTMSs in biotechnology and pharmaceutical companies to manage the planning, performance, and reporting functions of participant contact information, while tracking deadlines & milestones, pushes the market growth. Furthermore, the growing prevalence of chronic diseases and the rapid growth in the clinical trials market are estimated to propel the market growth during the forecast period.

On the other hand, the high costs associated with the purchase & maintenance of clinical trial management software is hampering the growth of the market. However, the increasing efficiency and efficacy that these systems provide would support the market growth throughout the assessment period, enhancing the overall management of clinical trial processes.

Global CTMS Market - Segments

The analysis is segmented into five main dynamics to widen the scope of understanding,

By Type : Enterprise CTMS and On-Site CTMS.

By Delivery Model : Web-Based (Hosted CTMS), Cloud-Based CTMS (SaaS), and Licensed Enterprise.

By Component : Software, Services, and Hardware.

By End User : Pharmaceutical & Biopharmaceutical Companies, Medical Device Manufacturers, Contract Research Organizations, and others.

By Regions : Americas, Europe, Asia-Pacific, Middle East & Africa, and Rest-of-the-World.

Clinical Trial Management System Market – Regional Analysis

North America leads the global clinical trial management system market. The largest market share attributes to the increasing numbers of clinical trials and the growing numbers of pharmaceutical & biotechnology companies in the region. Besides, factors such as the massive uptake of CTMS and augmenting market demand led by the importance of clinical data foster the regional market growth. Also, increasing advancements in digital medical technology in this region are expected to propel the growth in the regional market.

Europe stands second in the global clinical trial management system market, heading with the augmenting demand for CTMS in the rising numbers of CMOs and CTOs. Besides, factors such as the proliferating healthcare and pharmaceutical sectors, led by the resurging economy in the region, are boosting the regional market growth. Also, increasing government funding provides impetus to the market growth in the region, driving the R&D activities for the drug discoveries.

The Asia Pacific region is emerging as a promising market for clinical trial management systems. Rapidly growing healthcare sector and the use of IT in the clinical trial management process are the other important factors that define the growth landscape of the market in the region. Also, the rapidly developing economy in the region fosters market growth, increasing the penetration of the clinical trial management system.

Clinical Trial Management System Market - Competitive Landscape

Fiercely competitive, the clinical trial management system market appears highly fragmented due to the presence of many large & small-scale players. These players invest substantially to form strategic partnerships and collaborations to gain a larger competitive advantage. They also invest in driving RD activities and in meeting their expansion plans. Through R&D, they drive technology launch, and to expand their global footprints, they acquire promising companies from emerging regions.

Major Players:

Players active in the global CTMS market include Forte Research Systems Inc., Medidata Solutions, Oracle, eClinForce, Inc., PAREXEL, iWeb Technologies, Bioclinica, IBM, Bio-Optronics, Datatrak, DSG, Veeva Systems, Mastercontrol, Mednet Solutions, ERT, Arisglobal, and DZS Software Solutions, among others.

Industry/ Innovation /Related News:

March 04, 2020 ---- WCG Clinical Services (the US), the world's leading provider of clinical trials solutions, announced that The Michael J. Fox Foundation for Parkinson's Research (MJFF) has introduced a redesigned version of its clinical study matching solution, powered by WCG CenterWatch iConnect - Fox Trial Finder. The iConnect platform will make clinical trials easier, offering a unique patient recruitment management system. Improved technology & features of the iConnect platform would advance medical research to find and connect to appropriate clinical trials.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

NOTE : Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Friday, 25 September 2020

Industry Analysis on Cancer Registry Software Market News, Trends, Size, Global Demand

Cancer Registry Software Market Overview

The worldwide cancer registry software market is likely to hold a market value of USD 56.4 million in 2019. The market has been anticipated to develop at a CAGR of 10.7% over the forecast period.

Cancer registry gathers information about the prevalence (incidence) of cancer, the variations of cancers that occur and their positions within the body, the range of cancer at the time of diagnosis (disease stage), and the available treatments that the patients can receive.

Get Premium Free Sample Report @ https://www.marketresearchfuture.com/sample_request/7852

Data gathered by state cancer registries allow public health practitioners to better address and understand the cancer problem. Registry data are vital for targeting programs related to risk-related behaviors (for instance, sun exposure and tobacco use) or on ecological risk factors (for instance, chemical and radiation exposures). Such information is also indispensable for identifying where and when cancer screening efforts should be improved and for tracking the cure offered to cancer patients. Additionally, reliable registry data are essential to a gamut of research endeavors, including those aimed at estimating the efficiency of cancer control, prevention, or treatment programs.

Cancer registry software is a software used for disease registry that is mostly used to maintain and establish a cancer incidence reporting system. It acts as a technology oriented informational resource for the study of cancer and its causes. This type of registry software is substantial as cancer is among the leading causes of global death and therefore the data collection on cancer cases from diagnosis through survival is useful to help recognize trends and eventually progress care for patients that are battling cancer. However, data security-related concerns, privacy and averseness to adopt progressive solutions may hinder the growth of the market over the forecast period.

Cancer Registry Software Market Studied By Top Key Players

The global cancer registry software market has been dominated by key players such as Rocky Mountain Cancer Data Systems, Onco, Inc., Elekta AB (PUB), McKesson Corporation, Electronic Registry Systems, Inc., C/Net Solutions, Ordinal Data Inc, McKesson Corporation, IBM, Conduent Inc, and Himagine Solutions Inc.

Cancer Registry Software Market Segmentation

The global cancer registry software market has been segmented into deployment model, type, functionality, database type, and end user.

Based on deployment model, the market has been segmented into on-premise models and cloud-based models.

Based on type, the market has been segmented into standalone software and integrated software.

Based on functionality, the market has been segmented into product outcome evaluation, patient care management, medical research, cancer reporting to meet state and federal regulations, and clinical studies.

Based on database type, the market has been segmented into public databases and commercial databases.

Based on end user, the market has been segmented into government organizations, medical device companies, hospitals & medical practices, biotechnology, pharmaceutical, research centers, and others.

Cancer Registry Software Market Regional Analysis

The Americas is expected to lead the global cancer registry software market owing to the growing incidence of cancer, increasing investment in research and development for innovation in the region, and innovative product development. Europe is likely to hold the second largest position in the worldwide cancer registry software market owing to the availability of investment for research and prevalence of strong academic & research base in the European economies. Asia-Pacific is likely to be the fastest growing market in the worldwide cancer registry software industry due to the shift of pharmaceutical companies to nations such as China and India, which are low-cost manufacturing regions. The Middle East & Africa has the least share of the worldwide cancer registry software market. Furthermore, the major share of the global cancer registry software market is likely to be held by the Middle East region pertaining to the surging government initiatives for the healthcare sector.

OBTAIN RESEARCH REPORT DETAILS WITH TOC @https://www.marketresearchfuture.com/reports/cancer-registry-software-market-7852

About Market Research Future:

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

NEWs: Blood Screening Market 2020 | Size | Share | Report | Growth and Forecast

The global blood screening market is a continually growing space. The market growth attributes to the rising blood screening procedures conducted for the diagnosis of various chronic diseases such as HIV, HCV, HBV, malaria, syphilis, and other infectious diseases. Besides, increasing screening tests conducted on the donated blood to lessen the risk of transfusion-transmitted infections (TTIs) foster the market growth excellently. Moreover, raising awareness about the importance of blood tests escalates market growth.

Request a Sample Copy to Understand the Impact of COVID-19 On Blood Screening Market @ https://www.marketresearchfuture.com/sample_request/6899

According to Market Research Future (MRFR), the global blood screening market is estimated to grow at 9.8% CAGR during the forecast period (2018–2023). Due to the complexity of Coronaviruses, numbers of blood screening tests are increasing. Besides, the immune biomarker test used in the treatment of COVID 19 to identify and quantify the human immune system’s response to the virus influence the growth of the market. Also, increasing numbers of blood donations and blood donors is a significant growth driver of the market.

Additionally, increasing per capita healthcare expenditures and the adoption of nucleic acid test (NAT) for blood screening, boost the growth of the market. The introduction of pathogen reduction technology and the demand of multiplex tests propel the market growth. Conversely, factors such as the high costs and lack of regulations for NAT devices are estimated to restrict the growth of the market. Also, the advent of alternative technologies limits the market growth.

Global Blood Screening Market – Segments

The report is segmented into four dynamics;

By Technology : Nucleic Acid Amplification Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Next-Generation Sequencing (NGS), Western Blotting, among others.

By Product and Services: Reagent and kits, Enzymes & Polymerases, Standards & Controls, Probes & Primers, Buffers, Nucleotides, Solutions, Immunosorbents, Instruments, Rental Purchase, Software & services, and others.

By End-Users : Hospitals, Clinics, Research Institutes & Academic Centers, Blood Banks, and others.

By Regions : Americas, Europe, Asia Pacific, and the Rest-of-the-World (RoW).

Global Blood Screening Market – Regional Analysis

North America dominates the global blood screening market. Market growth attributes to the early adoption of advanced medical technologies and continuous development by companies operating into drugs. Besides, factors such as large numbers of industry players and well-developed healthcare sectors in the region boost market growth.

Moreover, the increasing occurrence of chronic diseases and the high per capita healthcare expenditures propel the regional market growth. The North American blood screening market is projected to retain its dominance over the global market throughout the assessment period.

Europe stands second in the global blood screening market. The market is driven by the rise in research expenses and the advancement of technology. Moreover, factors such as increasing health concerns and the demand for innovative and effective therapies boost the regional market growth. In Europe, the blood screening market is growing due to the well-spread awareness for blood screening tests and initiatives undertaken by private and public organizations.

Also, the growing prevalence of various hematological disorders and chronic diseases pushes regional market growth. Furthermore, the presence of prominent market players in the region impacts market growth positively. The European blood screening market is estimated to create a substantial revenue pocket during the forecast period.

The Asia pacific blood screening market has emerged as a promising market, globally. Factors such as the increasing number of blood transfusion procedures, increasing government initiatives, and technological advances drive the regional market growth. Moreover, the rising adoption rate of blood screening tests and increasing healthcare expenditure of demographics foster the growth of the market. China and India are hotspots for investment opportunities due to the growing numbers of diagnosis, treatment, and research activities, healthcare modernization, and quality improvisations.

Global Blood Screening Market – Competitive Analysis

Fiercely competitive, the blood screening market appears fragmented due to the presence of several well-established players. Through the strategic initiatives such as mergers & acquisitions, collaboration, expansion, and product & technology launch, these players try to gain a larger competitive share in the market.

Major Players:

Players leading the global blood screening market are F. Hoffmann-La Roche, Grifols, Abbott Laboratories, Bio-Rad Laboratories, Inc., Biomérieux, Siemens Healthineers (A Subsidiary of Siemens AG), Thermo Fisher Scientific, Inc., Ortho Clinical Diagnostics, Inc., Beckman Coulter (A Subsidiary of Danaher Corporation), and Becton, Dickinson, and Company, among others.

For more information in the analysis of this report, visit: https://www.marketresearchfuture.com/reports/blood-screening-market-6899

Industry, Innovation & Related News

Jun 15, 2020 ---- Cambridge Bioscience, a biotechnology company, announced filling a new patent for the company’s innovative FSIF (Full Spectrum Interferon Fingerprint) COVID-19 test. While the technology behind this newly filed patent will serve as an accurate diagnostic for COVID-19, its real value is the ability to stratify patients into degrees of disease severity, as noted in the pictured grid.

Jun 10, 2020 ---- Arkansas Blood Institute, a state governed blood center in the US state, announced free COVID-19 antibody tests for all blood donors. Arkansas Blood Institute is first to offer COVID-19 antibody screening service to donors. The testing initiative is provided at all donor centers and mobile blood drives. This comes in the wake of an immediate need for blood donations due to an unprecedented number of blood drive cancellations.

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

Biopharmaceuticals market Demand, Global Growth and Regional Forecast till 2025

Market Analysis

The global biopharmaceuticals market is projected to touch USD 394,998.5 million at an 8.99% CAGR between 2019-2025, as per the recent Market Research Future (MRFR) report. Biopharmaceuticals, simply put, are medical drugs that are produced using biotechnology. It comprises nucleic acids, proteins, living cells, sugars, or tissues used for in vivo diagnostic or therapeutic purposes and produced through ways other than extraction from native biological sources directly.

Numerous factors are adding to the global biopharmaceuticals market growth. These factors, according to the recent Market Research Future report, include constant technological advances, rising prevalence of chronic diseases, increasing geriatric population, rising acceptance of biopharmaceuticals for its ability to treat previously untreatable diseases, and huge investments made on R&D of biopharmaceuticals by major companies.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8439

On the contrary, strict government regulations, side effects from high use of biopharmaceuticals, and the availability of cost-effective biosimilars are factors that may limit the global biopharmaceuticals market growth over the forecast period.

Market Segmentation

The Market Research Future report provides an all-inclusive segmental analysis of the global biopharmaceuticals market based on application and product type.

By product type, the global biopharmaceuticals market is segmented into synthetic immunomodulators, vaccines, recombinant hormones, recombinant proteins, purified proteins, recombinant growth factors, monoclonal antibodies, and others. Recombinant growth factors are again segmented into granulocyte colony-stimulating factor and erythropoietin. Purified proteins are again segmented into P38 protein, P53 protein, leukemia inhibitory factor (LIF), and others. Recombinant proteins are again segmented into transferrin, defensin, amyloid protein, serum albumin, and others. Vaccines are again segmented into conventional vaccines, recombinant vaccines, and others. Recombinant vaccines are again segmented into cholera vaccines, diphtheria vaccines, tetanus vaccines, hepatitis B vaccines, Ebola vaccines, malaria vaccines, cancer vaccines, and others. Conventional vaccines are again segmented into pox vaccines, polio vaccines, and others. Synthetic immunomodulators are again segmented into tumor necrosis factor, interleukins, interferons, cytokines, and others. Of these, monoclonal antibodies will lead the market over the forecast period for the rising number of research activities, which are supported through the use of monoclonal antibodies. Meanwhile, vaccines are predicted to grow at the fastest CAGR for the increasing awareness of chronic diseases.

By application, the global biopharmaceuticals market is segmented into neurological diseases, cardiovascular diseases, disease prevention, hormonal disorders, metabolic disorders, autoimmune disorders, inflammatory and infectious diseases, oncology, and others. Of these, the oncology segment will dominate the market during the forecast period for the rising prevalence of cancer. Meanwhile, the neurological diseases will grow at the fastest CAGR over the forecast period for the increasing incidence of epilepsy and Parkinson’s disease.

Regional Analysis

By region, the global biopharmaceuticals market report covers the latest trends and growth opportunities across the Americas, the Asia Pacific (APAC), Europe, and the Middle East and Africa (MEA). Of these, the Americas will spearhead the market over the forecast period for the rising prevalence of various chronic diseases, especially cancer. Besides, the presence of several key pharmaceutical companies in the region is also adding market growth.

The global biopharmaceuticals market in Europe is predicted to have the second-largest share in the market during the forecast period for the rising prevalence of neurological diseases, well-developed healthcare infrastructure, and rising geriatric population.

The global biopharmaceuticals market in the APAC region is predicted to grow at the fastest pace over the forecast period for the rising prevalence of cancer and diabetes and a supportive regulatory framework for the approval of biopharmaceuticals.

The global biopharmaceuticals market in the MEA will have significant growth during the forecast period for the increasing patient population that is suffering from different chronic diseases. The market in the Middle East will have higher growth for the presence of two developed countries- Oman and Saudi Arabia.

Key Players

Notable players profiled in the global biopharmaceuticals market report include Biocon (India), Merck KGaA (Germany), GlaxoSmithKline PLC (UK), Novo Nordisk A/S (Denmark), Sandoz International GmbH (Germany), Bristol-Myers Squibb Company (US), Sanofi (France), Abbvie Inc. (US), AstraZeneca (UK), Gilead Sciences, Inc. (US), Johnson & Johnson (US), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lilly and Company (US), Amgen Inc. (US), and Pfizer Inc. (US).

Industry News

Jan 2020: Celltrion Group will soon build the largest biopharmaceutical plant in China with a production capacity of 120,000 liters.

About Market Research Future:

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

Analysis Report: Angioplasty Balloons Market Size, News, Demand, Report and Forecast

Market Analysis

The angioplasty balloons market is anticipated to touch USD 3457.35 million at a 5.01% CAGR between 2022- 2027, according to the new report by Market Research Future (MRFR). Angioplasty is a minimally invasive endovascular technique used to widen obstructed or narrowed veins or arteries, generally to treat arterial atherosclerosis. Scoring balloons, drug eluting balloons, cutting balloons, and normal balloons are the different types of angioplasty balloons that have wide applications in peripheral artery disease and coronary artery disease. They are widely used in ambulatory surgical centers, cardiac catheterization laboratories, hospitals, and others.

Get Free Sample copy @ https://www.marketresearchfuture.com/sample_request/9614

Various factors are adding to the global angioplasty balloons market growth. According to the new MRFR report, such factors include increasing number of clinical trials by top market players, rising number of product launches, growing initiatives by private & public organizations to create awareness about angioplasty treatment options, rising prevalence of cardiac diseases, demand for minimally invasive procedures, and technological advances in balloons.

On the contrary, increasing focus to treat COVID-19 patients has put cardiac surgeries on halt along with disruption in the supply chain, thereby limiting the global angioplasty balloons market growth.

Market Segmentation

The MRFR report gives an inclusive segmental analysis of the global angioplasty balloons market report based on end user, application, and product type.

By product type, the global angioplasty balloons market is segmented into scoring balloons, drug eluting balloons, cutting balloons, and normal balloons. Of these, normal balloons will lead the market over the forecast period for its high preference rate and widespread use.

By application, the global angioplasty balloons market is segmented into peripheral artery disease and coronary artery disease. Of these, coronary artery disease will dominate the market over the forecast period for the increase in cardiac cases worldwide.

By end user, the global angioplasty balloons market is segmented into ambulatory surgical centers, cardiac catheterization laboratories, hospitals, and others. Of these, hospitals will have lions share in the market over the forecast period.

Regional Analysis

Based on the region, the global angioplasty balloons market report covers the growth opportunities and recent trends across the Americas, Europe, the Asia Pacific (APAC), & the Middle East and Africa (MEA). Of these, the Americas will dominate the market over the forecast period. The presence of eminent players, coupled with tie-ups by several companies to expand geographical footprints, is adding to the global angioplasty balloons market growth in the region.

The global angioplasty balloons market in Europe is predicted to hold the second-largest share over the forecast period. The presence of leading industry players and different strategies undertaken by these players to strengthen their presence, such as mergers and acquisitions and joint ventures coupled with increased hospitalizations for cerebral angioplasty and carotid artery angioplasty is adding to the global angioplasty balloons market growth in the region.

The global angioplasty balloons market in the APAC region is predicted to grow at a fast pace over the forecast period. Manufacturers are making vigorous marketing activities to increase potential targets which in turn is adding to the global angioplasty balloons market growth in the region.

The global angioplasty balloons market in the MEA will have the smallest share over the forecast period but is predicted to grow in the future for the inclination of top companies to untapped regions.

Key Players

Key players profiled in the global angioplasty balloons market report include Endocor (Germany), Cordis (Cardinal Health) (US), Terumo Medical Corporation (Japan), Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), Cook (US), Boston Scientific Corporation (US), C.R. Bard (BD) (US), Biotronik SE & Co. KG (Germany), Abbott (US), and B. Braun Melsungen AG (Germany). Industry players have incorporated strategies such as mergers, partnerships, joint ventures, new product launches, and acquisitions to create a niche in the market.

About Market Research Future:

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

Latest Research On Alpha-1 Antitrypsin Deficiency Treatment Market Forecast till 2025

Global Alpha-1 Antitrypsin Deficiency Treatment Market.

Market Forecast

Registering a CAGR of 10.50%, the Global Alpha-1 Antitrypsin Deficiency Treatment Market share is expected to grow from USD 1,464.1 Million in 2018 to USD 2,914.7 Million by 2025.

As of July 2019, 3.4 million people are affected by alpha-1 antitrypsin deficiency worldwide. The disorder is found to affect populations in all the regions of the world.

The market is dominated by numerous established players. The key players are involved in product launches, strategic collaborations, and awareness programs to strengthen their market positions. For instance, in November 2018, Grifols S. A. launched the AlfaCare therapy program for training and counseling of patients diagnosed with alpha-1 antitrypsin deficiency.

Market Influencer

The prevalence of alpha-1 antitrypsin deficiency (AATD) is increasing, which is directly responsible for the growth of the global alpha-1 antitrypsin deficiency treatment market. Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major competitors are expected to further boost market growth during the forecast period.

Segmentation

By Drugs:

Alpha-1 Proteinase Inhibitor: The segment is expected to hold the largest market share as it is the only treatment for AATD, which protects the patient from more lung damage.
Bronchodilators: These are used for the treatment of respiratory disorders associated with AATD.
Steroids: These are used specifically for the treatment of chronic obstructive pulmonary disease, which affects the patient along with AATD.
Others: Other treatment options include antibiotics for infections and jaundice associated with AATD and oxygen therapy.

By Route of Administration:

Oral: The segment is expected to hold the largest market share.
Intravenous: The segment is expected to grow at the fastest CAGR.
Inhalation: This route of administration is used specifically for the administration of corticosteroids for treating breathing disorders.
Others: Subcutaneous and intramuscular routes of administration.

By Distribution Channel:

Hospital Pharmacy: The rise in the number of hospitals is likely to be responsible for the largest market size.
Retail Pharmacy: These fulfill the requirement of drugs that are needed for treatment at home.
Online Stores: The fastest-growing segment owing to increase in number of online pharmacies.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/alpha-1-antitrypsin-deficiency-treatment-market-8319

By Region

Americas: The region holds the largest share of the market. The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

Europe: The European alpha-1 antitrypsin deficiency treatment market has been classified as Western Europe and Eastern Europe. The Western European market has further been categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

Asia-Pacific: The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific alpha-1 antitrypsin deficiency treatment market is projected to be the fastest-growing during the forecast period.

Middle East & Africa: The market in the Middle East & Africa has been divided into the Middle East and Africa.

Key Players

Kamada Pharmaceuticals (Israel)
CSL Behring LLC (US)
Grifols, S.A. (Spain)
Takeda Pharmaceutical Company Limited (Japan)
GlaxoSmithKline plc (UK)
Boehringer Ingelheim GmbH (Germany)
AstraZeneca (UK)
Vectura Group plc (UK)
Pfizer Inc. (US)
Mylan Inc. (US)

About Market Research Future:

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

Global Analysis On Acute myeloid leukemia (AML) Market Size, Share and Regional Growth

Market Scenario

Acute myeloid leukemia (AML) is a cancer of the myeloid blood cells, causing extreme and rapid growth of abnormal white blood cells of the bone marrow. The rapid buildup of abnormal white blood cells causes interference in the production of normal blood cells. AML has a propensity to increase towards age. Replacement of normal bone marrow with cancer cells causes a drop in blood constituents such as red blood cells, platelets, white blood cells etc. which causes symptoms such as fatigue, breathlessness, easy bruising and bleeding, and increased risk of infection. The market driving factors for acute myeloid leukemia (AML) are rise in risk factors such as exposures to carcinogens such as ionizing radiation, chemicals etc. Presence of other blood disorders and genetics is also involved for the higher risk of AML. Other market drivers are increasing number of cancer hospitals, greater awareness, good reimbursement scenario etc. The market constraints are poor cure rates of the present drugs, serious side effects of the drugs etc.

Considering all these factors the market for acute myeloid leukemia treatment is expected to reach $ 1.2 billion by the end of 2023, this market is projected to growing at a CAGR of Approx 5.3 % during 2017-2023.
Key players of Global Acute Myeloid Leukemia Treatment Market

Key players profiled in the report are Johnson & Johnson, Pfizer Inc., Celgene Corporation, Ambit Biosciences Corporation, Cyclacel Pharmaceuticals Inc. Novartis AG and Sanofi, Bristol Myers Squibb and others.

Segments

The global acute myeloid leukemia treatment market is segmented on the basis of disease type. Based on the disease type, the market has been segmented as myeloblastic, promyeloctic, myelomonocytic, monocytic, erythroleukemia and megakaryocytic. Based on the treatment, the market has been segmented as chemotherapy, and hematopoietic stem cell transplantation. Chemotherapy is further sub-segmented into induction and post remission.

Intended Audience

Global acute myeloid leukemia treatment solutions providers.
Research and development (R&D) companies
Market research and consulting service providers
Academic institutes and universities

Regional Analysis

US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. Europe is the second largest market due to large disposable income and presence of large hospitals. Asia pacific region will be the fastest region because of large unmet needs which will be led by China and India. The Middle East and Africa market will be led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa is expected to be a laggard due to poor economic and political conditions.

The report for Global Acute myeloid leukemia treatment Market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Market Scenario

Key players of Global Acute Myeloid Leukemia Treatment Market

Segments

The global acute myeloid leukemia treatment market is segmented on the basis of disease type. Based on the disease type, the market has been segmented as myeloblastic, promyeloctic, myelomonocytic, monocytic, erythroleukemia and megakaryocytic. Based on the treatment, the market has been segmented as chemotherapy, and hematopoietic stem cell transplantation. Chemotherapy is further sub-segmented into induction and post remission.

Intended Audience

Global acute myeloid leukemia treatment solutions providers.
Research and development (R&D) companies
Market research and consulting service providers
Academic institutes and universities

Regional Analysis

About Market Research Future:

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

Industry Analysis Reports | Health Care | Medical Devices | Pharmaceutical

Labels

Sunday, 27 September 2020

Clinical Trial Management System Market reaching the value of USD 1,106.76 million with CAGR 12.0% by 2025

Friday, 25 September 2020

Industry Analysis on Cancer Registry Software Market News, Trends, Size, Global Demand

NEWs: Blood Screening Market 2020 | Size | Share | Report | Growth and Forecast

Biopharmaceuticals market Demand, Global Growth and Regional Forecast till 2025

Analysis Report: Angioplasty Balloons Market Size, News, Demand, Report and Forecast

Latest Research On Alpha-1 Antitrypsin Deficiency Treatment Market Forecast till 2025

Global Analysis On Acute myeloid leukemia (AML) Market Size, Share and Regional Growth

Blog Archive

Total Pageviews